Login / Signup

Phase II trial of daily S-1 combined with weekly irinotecan in previously treated patients with advanced or recurrent squamous cell lung cancer: North Japan lung cancer group 1101.

Yosuke KawashimaOsamu IshimotoEisaku MiyauchiTomohiro SakakibaraToshiyuki HaradaKazuhiro UsuiAkira InoueShunichi Sugawara
Published in: Thoracic cancer (2023)
Although the treatment-related adverse events were manageable, the combination of weekly irinotecan and S-1 did not have the expected effect.
Keyphrases
  • squamous cell
  • physical activity
  • open label
  • randomized controlled trial
  • tertiary care
  • replacement therapy
  • study protocol
  • placebo controlled